Faculty of Medicine Universitas Sumatera Utara
Medan, North Sumatera, 20155, Indonesia
NCT Number: NCT04634188
This study is a case controlled analytical study that analyzes the relationship between levels of inflammatory markers with the type of brain tumor. Samples of 35 people were then categorized according to the variables above and analyzing to measure its significance
Looking for future studies?
Notify Me18 year–70 year
All sexes
Observational
Medan, North Sumatera, 20155, Indonesia
This study is a case controlled analytical study to find the relationship between levels of inflammatory markers in patients with brain tumors. Samples were collected from patients at Haji Adam Malik Hospital in Medan, then the patient's blood serum was taken to be checked for these variables. Sample collection began in March - September 2020. The sample obtained was 35 people who met the inclusion and exclusion criteria.
Inclusion criteria
Exclusion criteria
Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically.
Based on this analysis, it will be determined whether there is a significant relationship between levels of inflammatory markers in the incidence of brain tumors.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically
Other names: C-Reactive Protein (CRP), Neutrophyl to Lymphocyte Ratio (NLR)
Time frame: February-April 2020
Value of Procalcitonin in each group (Meningioma Group, Glioma Group and Brain metastasis group)
Time frame: April- June 2020
Value of C-Reactive Protein in each group (Meningioma Group, Glioma Group and Brain metastasis group)
Time frame: June- August 2020
Value of NLR in each group (Meningioma Group, Glioma Group and Brain metastasis group)
Time frame: August- October 2020
Demographic of each samples such as age, gender, Glassgow coma scale and Karnofsky score
Universitas Sumatera Utara
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02153957
Behavior, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT02851706
Astrocytoma, Brain Cancer
Bethesda, Maryland, United States
View Trial DetailsNCT06368310
Brain Diseases, Brain Neoplasms
Salford, Greater Manchester, United Kingdom
View Trial DetailsNCT05776602
Brain Diseases, Brain Neoplasms
Stockholm, Stockholm County, Sweden
View Trial Details